Search Results
Results found for "Evaxion Biotech"
- Dr. Yamina Berchiche: Beyond the Lab — From Chemokine Receptors to the Dr. GPCR Ecosystem | Dr. GPCR Ecosystem
outside clinical attention Career architecture for bench pharmacologists moving beyond academia and biotech
- Pod-Be Our Guest - Public | Dr. GPCR Ecosystem
GPCR Podcast features leading scientists, innovators, and biotech professionals whose work is advancing
- Dr. Tore Bengtsson: Rethinking β₂-Adrenergic Signaling in Metabolic Disease | Dr. GPCR Ecosystem
He is also an entrepreneur and founder of biotechnology companies translating GPCR pharmacology into Early research on brown adipose tissue and thermogenesis 22:30 Translating academic discoveries into biotech
- Dr. Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem
I’m currently a senior scientist at a biotech in Toronto, Canada. But as I grew up and learned more about biotechnology and the possibilities that existed, my interests
- Dr. Joseph Kim: Structural Biology and Drug Discovery at GPCRs | Dr. GPCR Ecosystem
I can imagine myself in a biotech or pharmaceutical environment where I’m helping guide drug development
- Dr. Fiona Marshall: Three Decades Inside GPCR Drug Discovery | Dr. GPCR Ecosystem
of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery and development biotechnology
- how-to-build-breakthrough-gpcr-programs | Dr. GPCR Ecosystem
As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel
- Dr. Shivani Sachdev | Dr. GPCR Ecosystem
She received her undergraduate degree in Biotechnology from KIIT University in India.
- Re-cap of Endocrine Metabolic GPCR 2024 with the Organizers | Dr. GPCR Ecosystem
Her work is currently funded by Biotechnology and Biological Sciences Research Council (BBSRC), Diabetes
- Dr. Katarzyna Marcinkiewicz | Dr. GPCR Ecosystem
following three years on the editorial teams of Nature Structural and Molecular Biology and Nature Biotechnology
- Julia Gardner | Dr. GPCR Ecosystem
Last summer, Julia worked at as the first-ever summer intern at Septerna, the GPCR-based biotechnology
- Dr. Timo De Groof | Dr. GPCR Ecosystem
Timo De Groof studied Biochemistry and Biotechnology at the University of Ghent where he graduated in During his master's studies, he specialized in Biomedical Biotechnology and Structural Biology/Biochemistry
- Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem
based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology
- Dr. Aylin Hanyaloglu | Dr. GPCR Ecosystem
Her work is currently funded by Biotechnology and Biological Sciences Research Council (BBSRC), Diabetes
- Irfan Dhanidina, Dr. Kathleen Caron and Dr. Lauren Slosky | Dr. GPCR Ecosystem
oncology research led me to pursue a BSc in Biology & Economics from Carleton University, and an MSc in Biotechnology In my role at Orion Biotechnology, I work at the intersection of science and business, which includes
- Dr. Kathryn E Livingston | Dr. GPCR Ecosystem
Kathryn E Livingston is currently a Product Manager at Gator Bio , a biotechnology company providing
- Dr. Ralf Jockers | Dr. GPCR Ecosystem
Ralf Jockers Ralf Jockers studied in Cologne and received a Ph.D. in biotechnology and biochemistry from
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
Andrew is translating fundamental findings to commercial products is Keltic Pharma Therapeutics Ltd , a biotechnology
- Dr. Patrick Sexton | Dr. GPCR Ecosystem
Sexton is also a co-founder of the San Francisco-based biotechnology company Septerna Inc . Dr.
- Dr. Oliver Hartley | Dr. GPCR Ecosystem
Oliver Hartley Oliver Hartley is VP for Drug Discovery at Orion Biotechnology . Oliver Hartley on the web LinkedIn Orion Biotechnology Dr.
- Dr. Arun Shukla: How Two Arrestins Regulate 800 GPCRs | Dr. GPCR Ecosystem
He earned his master's degree in biotechnology from Jawaharlal Nehru University in India and it was during
- Fresh, Fresh, GPCR News ❇ Feb 17 - 23, 2025 | Dr. GPCR Ecosystem
networking, mentorship, PhD resilience, COVID-19 challenges, and his aspiration to transition into biotechnology





















